<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="authors contributed equally. TPV is a member of the Pan" exact="African" post="Network for Rapid Research, Response, and Preparedness for Infectious"/>
 <result pre="Pan African Network for Rapid Research, Response, and Preparedness for" exact="Infectious" post="Diseases Epidemics consortium (PANDORAâ€�IDâ€�NET; RIA2016Eâ€�1609). epub: 2020-2-2ppub: 2020-325310.1111/tmi.v25.3278280(C) ,"/>
 <result pre="African Network for Rapid Research, Response, and Preparedness for Infectious" exact="Diseases" post="Epidemics consortium (PANDORAâ€�IDâ€�NET; RIA2016Eâ€�1609). epub: 2020-2-2ppub: 2020-325310.1111/tmi.v25.3278280(C) , This"/>
 <result pre=", This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
 <result pre="source, for the duration of the public health emergency.file:TMI-25-278.pdf COVIDâ€�19" exact="Epidemic" post="SARSâ€�CoV2 Wuhan 2019â€�nCoV fig-count: table-count: page-count: word-count: The current"/>
 <result pre="word-count: The current outbreak of the novel coronavirus SARSâ€�CoVâ€�2 (coronavirus" exact="disease" post="2019; previously 2019â€�nCoV), epiâ€�centred in Hubei Province of the"/>
 <result pre="viruses from patients with common colds 2. Based on their" exact="morphology" post="as spherical virions with a core shell and surface"/>
 <result pre="coronaviruses that can infect humans, the betaâ€�coronaviruses may cause severe" exact="disease" post="and fatalities, whereas alphaâ€�coronaviruses cause asymptomatic or mildly symptomatic"/>
 <result pre="severe disease and fatalities, whereas alphaâ€�coronaviruses cause asymptomatic or mildly" exact="symptomatic" post="infections. SARSâ€�CoVâ€�2 belongs to the B lineage of the"/>
 <result pre="seafood market in Wuhan, China. However, endeavours to identify potential" exact="intermediate" post="hosts seem to have been neglected in Wuhan and"/>
 <result pre="to be clarified. The initial clinical sign of the SARSâ€�CoVâ€�2â€�related" exact="disease" post="COVIDâ€�19 which allowed case detection was pneumonia. More recent"/>
 <result pre="infected by SARSâ€�CoVâ€�2 who remain asymptomatic throughout the course of" exact="infection" post="has not yet been definitely assessed. In symptomatic patients,"/>
 <result pre="course of infection has not yet been definitely assessed. In" exact="symptomatic" post="patients, the clinical manifestations of the disease usually start"/>
 <result pre="definitely assessed. In symptomatic patients, the clinical manifestations of the" exact="disease" post="usually start after less than a week, consisting of"/>
 <result pre="of fever, cough, nasal congestion, fatigue and other signs of" exact="upper" post="respiratory tract infections. The infection can progress to severe"/>
 <result pre="fever, cough, nasal congestion, fatigue and other signs of upper" exact="respiratory" post="tract infections. The infection can progress to severe disease"/>
 <result pre="fatigue and other signs of upper respiratory tract infections. The" exact="infection" post="can progress to severe disease with dyspnoea and severe"/>
 <result pre="upper respiratory tract infections. The infection can progress to severe" exact="disease" post="with dyspnoea and severe chest symptoms corresponding to pneumonia"/>
 <result pre="infection can progress to severe disease with dyspnoea and severe" exact="chest" post="symptoms corresponding to pneumonia in approximately 75% of patients,"/>
 <result pre="severe disease with dyspnoea and severe chest symptoms corresponding to" exact="pneumonia" post="in approximately 75% of patients, as seen by computed"/>
 <result pre="of patients, as seen by computed tomography on admission 8." exact="Pneumonia" post="mostly occurs in the second or third week of"/>
 <result pre="mostly occurs in the second or third week of a" exact="symptomatic" post="infection. Prominent signs of viral pneumonia include decreased oxygen"/>
 <result pre="or third week of a symptomatic infection. Prominent signs of" exact="viral pneumonia" post="include decreased oxygen saturation, blood gas deviations, changes visible"/>
 <result pre="third week of a symptomatic infection. Prominent signs of viral" exact="pneumonia" post="include decreased oxygen saturation, blood gas deviations, changes visible"/>
 <result pre="include decreased oxygen saturation, blood gas deviations, changes visible through" exact="chest" post="Xâ€�rays and other imaging techniques, with ground glass abnormalities,"/>
 <result pre="affected individuals every seven days and that each patient spreads" exact="infection" post="to 2.2 other individuals on average (R0) 6. Estimates"/>
 <result pre="due to dense traffic between China and Africa. Very few" exact="African" post="countries have sufficient and appropriate diagnostic capacities and obvious"/>
 <result pre="or, if so, may show milder symptoms or even asymptomatic" exact="infection" post="7. As of 13. February 2020, the case fatality"/>
 <result pre="of 13. February 2020, the case fatality rate of COVIDâ€�19" exact="infections" post="has been approximately 2.2% (1370/60363; 13. February 2020, 06:53"/>
 <result pre="since 2012 12. Like other viruses, SARSâ€�CoVâ€�2 infects lung alveolar" exact="epithelial" post="cells using receptorâ€�mediated endocytosis via the angiotensinâ€�converting enzyme II"/>
 <result pre="AP2â€�associated protein kinase 1 (AAK1) disrupting these proteins may inhibit" exact="viral" post="entry into the target cells 13. Baricitinib, used in"/>
 <result pre="the target cells 13. Baricitinib, used in the treatment of" exact="rheumatoid arthritis," post="is an AAK1 and Janus kinase inhibitor and suggested"/>
 <result pre="an AAK1 and Janus kinase inhibitor and suggested for controlling" exact="viral" post="replication 13. Moreover, one in vitro and a clinical"/>
 <result pre="indicate that remdesivir, an adenosine analogue that acts as a" exact="viral" post="protein inhibitor, has improved the condition in one patient"/>
 <result pre="pH required for virusâ€�cell fusion, has the potential of blocking" exact="viral infection" post="15 and was shown to affect activation of p38"/>
 <result pre="required for virusâ€�cell fusion, has the potential of blocking viral" exact="infection" post="15 and was shown to affect activation of p38"/>
 <result pre="of which have shown survival benefits in several deadly virus" exact="infections" post="and are being considered as potential treatment candidates 18."/>
 <result pre="these available drugs for immediate use in treatment in SARSâ€�CoVâ€�2" exact="infections" post="could improve the currently available clinical management. Clinical trials"/>
 <result pre="transplantation 19. Given the fragile health systems in most subâ€�Saharan" exact="African" post="countries, new and reâ€�emerging disease outbreaks such as the"/>
 <result pre="health systems in most subâ€�Saharan African countries, new and reâ€�emerging" exact="disease" post="outbreaks such as the current COVIDâ€�19 epidemic can potentially"/>
 <result pre="epidemic can potentially paralyse health systems at the expense of" exact="primary" post="healthcare requirements. The impact of the Ebola epidemic on"/>
 <result pre="and preparedness during emergencies of such magnitude are challenging across" exact="African" post="and other lowerâ€�middleâ€�income countries. Such situations can partly only"/>
 <result pre="partly only be mitigated by supporting existing regional and subâ€�Saharan" exact="African" post="health structures. References References 1collab: Coronavirus 2019â€�nCoV, CSSE ."/>
 <result pre="(nCoV). (Available from: https://nextstrain.org/groups/blab/sars-like-cov). 4ZhouP, YangXL, WangXG et al. A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="Media. (Available from: https://link.springer.com/content/pdf/10.1007%2F978-1-4899-1531-3_6.pdf). 6ChanJF, YuanS, KokKH et al. A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
 <result pre="https://link.springer.com/content/pdf/10.1007%2F978-1-4899-1531-3_6.pdf). 6ChanJF, YuanS, KokKH et al. A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating personâ€�toâ€�person transmission:"/>
 <result pre="8GuanW, NiZ, YuH, et al.Clinical characteristics of 2019 novel coronavirus" exact="infection" post="in China. medRxiv preprint posted online on Feb. 9,"/>
 <result pre="Lloydâ€�SmithJO, CoffeeMP, GalvaniAP. Dynamically modeling SARS and other newly emerging" exact="respiratory" post="illnesses: past, present, and future. Epidemiology2005: 6: 791â€&quot;801. 10ZhaoS,"/>
 <result pre="Health Organization . Cumulative Number of Reported Probable Cases of" exact="Severe" post="Acute Respiratory Syndrome (SARS). 2020. (Available from: http://www.who.int/csr/sars/country/en/.) 12collab:"/>
 <result pre="Organization . Cumulative Number of Reported Probable Cases of Severe" exact="Acute" post="Respiratory Syndrome (SARS). 2020. (Available from: http://www.who.int/csr/sars/country/en/.) 12collab: World"/>
 <result pre=". Cumulative Number of Reported Probable Cases of Severe Acute" exact="Respiratory" post="Syndrome (SARS). 2020. (Available from: http://www.who.int/csr/sars/country/en/.) 12collab: World Health"/>
 <result pre="Cumulative Number of Reported Probable Cases of Severe Acute Respiratory" exact="Syndrome" post="(SARS). 2020. (Available from: http://www.who.int/csr/sars/country/en/.) 12collab: World Health Organization"/>
 <result pre="http://www.who.int/csr/sars/country/en/.) 12collab: World Health Organization . WHO 2019, Middle East" exact="respiratory" post="syndrome coronavirus (MERSâ€�CoV). (Available from: https://www.who.int/emergencies/mers-cov/en/.) 13RichardsonP, GriffinI, TuckerC"/>
 <result pre="12collab: World Health Organization . WHO 2019, Middle East respiratory" exact="syndrome" post="coronavirus (MERSâ€�CoV). (Available from: https://www.who.int/emergencies/mers-cov/en/.) 13RichardsonP, GriffinI, TuckerC et"/>
 <result pre="GriffinI, TuckerC et al. Baricitinib as potential treatment for 2019â€�nCoV" exact="acute" post="respiratory disease. Lancet2020S0140-6736(20)30304-4. 10.1016/S0140-6736(20)30304-4 14HolshueML, DeBoltC, FirstLindquist S et"/>
 <result pre="TuckerC et al. Baricitinib as potential treatment for 2019â€�nCoV acute" exact="respiratory" post="disease. Lancet2020S0140-6736(20)30304-4. 10.1016/S0140-6736(20)30304-4 14HolshueML, DeBoltC, FirstLindquist S et al."/>
 <result pre="TatsumiK, ImaiAM, SaitoK, KuriyamaT, ShirasawaH. Inhibition of human coronavirus 229E" exact="infection" post="in human epithelial lung cells (L132) by chloroquine: involvement"/>
 <result pre="KuriyamaT, ShirasawaH. Inhibition of human coronavirus 229E infection in human" exact="epithelial" post="lung cells (L132) by chloroquine: involvement of p38 MAPK"/>
</results>
